64 completed, 3 active not recruiting, 2 unknown, 1 withdrawn. 32 Phase 3, 16 Phase 4, 12 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 32 | Completed 29, Active not recruiting 2, Unknown 1 |
| Phase 4 | 16 | Completed 14, Active not recruiting 1, Unknown 1 |
| Phase 2 | 12 | Completed 11, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
Follow RIX4414 vaccine: new trials by email Literature Review of RIX4414 vaccine trials Research Report on RIX4414 vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| How Gut Health Affects Immune Responses to the Oral Rotavirus Vaccine in Adults in Zambia Rotarix®, - Feasibility Study, Vaccine Immune Response | Completed | Centre for Infectious Disease Research in Zambia | 46 | 2026-03-30 | 2026-11-03 | |
| Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine - Pneumococcal Immunization | Phase 3 | Active not recruiting | Sanofi | 580 | 2025-02-27 | 2026-02-13 |
| Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine - Pneumococcal Immunization | Phase 3 | Active not recruiting | Sanofi | 2360 | 2025-02-18 | 2026-04-13 |
| Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks GSK's liquid oral live attenuated HRV, PCV-free liquid formulation of GSK's oral live attenuated HRV - Gastroenteritis | Phase 3 | Completed | GlaxoSmithKline | 2000 | 2023-09-01 | 2025-05-09 |
| ROTA-biotic: Measuring the Impact of Rotavirus Vaccines on Paediatric Antibiotic Usage Vaccine - Rotavirus Gastroenteritis, Rotavirus Vaccines | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1600 | 2021-05-04 | 2025-03-18 | |
| Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa Rotarix, Trivalent P2-VP8 - Diarrhea, Diarrhea Rotavirus | Phase 2 | Completed | Centre for Infectious Disease Research in Zambia | 720 | 2021-04-15 | 2025-05-15 |
| Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine RV3-BB, Trivalent P2-VP8, Rotarix - Rotavirus Vaccine | Phase 2 | Completed | PATH | 850 | 2021-02-22 | 2022-11-29 |
| Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus), DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b), Inactivated Poliomyelitis Vaccine - Pertussis Immunisation, Diphtheria Immunisation | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 460 | 2020-06-28 | 2025-09-22 |
| A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India TV P2-VP8, Rotarix - Rotavirus Infection of Children | Phase 3 | Unknown | PATH | 8200 | 2019-10-10 | 2021-04-09 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) Rotarix™, Infanrix™ hexa, V114 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1184 | 2019-09-04 | 2023-07-28 |
| Response to Rotavirus Vaccine in Infants in Ho Chi Minh City in Vietnam Rotarix vaccine - Rotavirus, Diarrhea | Phase 4 | Completed | Oxford University Clinical Research Unit, Vietnam | 818 | 2019-03-19 | 2022-11-14 |
| Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia ROTAVAC®, ROTAVAC 5D, Rotarix® - Diarrhea, Diarrhea Rotavirus | Phase 2 / Phase 3 | Completed | Centre for Infectious Disease Research in Zambia | 450 | 2019-01-22 | 2020-12-19 |
| Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine, Meningococcal group B vaccine, Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine - Healthy Volunteers (Meningococcal Infection) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 788 | 2018-10-10 | 2023-11-07 |
| Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 1196 | 2018-07-27 | 2026-08-20 |
| Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants MT-5625 low dose, MT-5625 middle dose, MT-5625 high dose - Healthy | Phase 1 | Completed | Tanabe Pharma Corporation | 110 | 2018-07-03 | 2019-08-06 |
| Optimising Rotavirus Vaccine in Aboriginal Children Rotarix (RV1), Placebo - Viral Gastroenteritis Due to Rotavirus | Phase 4 | Active not recruiting | Telethon Kids Institute | 1000 | 2018-03-27 | 2024-03-06 |
| This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine Rotarix, Pediarix, Hiberix - Rotavirus Infection, Rotavirus Vaccines | Phase 3 | Completed | GlaxoSmithKline | 1280 | 2017-09-14 | 2020-12-29 |
| The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity Rotarix, dose 1, Rotarix, dose 2, Placebo (for Rotarix dose 2) - Rotavirus Infection, Vaccine Response Impaired | Phase 4 | Completed | University of Vermont | 220 | 2017-06-12 | 2020-08-04 |
| Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks HRV PCV-free liquid vaccine, Rotarix - Infections, Rotavirus, Rotavirus Vaccines | Phase 3 | Completed | GlaxoSmithKline | 1612 | 2016-10-27 | 2020-07-21 |
| Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Squarekids, Rotarix - Rotavirus | Phase 4 | Completed | GlaxoSmithKline | 292 | 2016-09-16 | 2019-11-25 |
Showing 20 of 70. Sign in to see all of them.
Rotavirus Infections (27) · Gastroenteritis (13) · Poliomyelitis (7) · Diarrhea (6) · Diphtheria (6) · Haemophilus Infections (6) · Pneumococcal Infections (6) · Tetanus (6) · Hepatitis B (5) · Intussusception (3) · Meningococcal Infections (3) · Streptococcal Infections (3) · Whooping Cough (3) · Meningitis (2) · Vomiting (2)
GlaxoSmithKline (37) · PATH (6) · Sanofi Pasteur, a Sanofi Company (4) · Centre for Infectious Disease Research in Zambia (3) · Sanofi (2) · University of Oxford (2) · University of Vermont (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Centers for Disease Control and Prevention (1) · Children's Hospital Medical Center, Cincinnati (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Merck Sharp & Dohme LLC (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Hygiene and Epidemiology, Vietnam (1) · National Institute of Pediatrics, Mexico (1)
United States (12) · Bangladesh (5) · Mexico (5) · South Africa (5) · Zambia (5) · South Korea (4) · Australia (3) · China (3) · Germany (3) · India (3) · Japan (3) · Philippines (3) · Spain (3) · United Kingdom (3) · Chile (2)
George Armah, PhD (2) · Roma Chilengi, MD (2) · Anh D Dang, PhD. (1) · Benjamin Lee, M.D. (1) · Beth Kirkpatrick, M.D. (1) · Desiree Witte, MD (1) · Dr Prasad Kulkarni, M.D. (1) · Gagandeep Kang, MD, PhD (1) · Janet Englund, MD (1) · K Zaman, MBBS, PhD (1) · K Zaman, PhD, MPH (1)
PMID 25424932, PMID 16394298, PMID 22520120, PMID 22974466, PMID 25278086, PMID 26035743, PMID 26318714, PMID 26643930, PMID 26823335, PMID 26823338, PMID 26823540, PMID 26870801, PMID 27154394, PMID 27217217, PMID 27494163, PMID 27895844, PMID 28079828, PMID 28293424, PMID 28419095, PMID 28425818, PMID 28444240, PMID 29390150, PMID 29394355, PMID 29514306, PMID 29564996, PMID 30104114, PMID 30376086, PMID 31104832, PMID 31607603, PMID 31727664, PMID 32035706, PMID 32157282, PMID 32843086, PMID 32867719, PMID 33109390, PMID 33245004, PMID 33428870, PMID 34454786, PMID 34565452, PMID 34788488, PMID 35134951, PMID 35144847, PMID 35961362, PMID 37105892, PMID 37257121, PMID 38463163, PMID 39052701, PMID 41319434, PMID 41495936
2015 (5), 2016 (3), 2014 (1), 2017 (1), 2018 (1)